타이틀

FDA approval of Lazertinib & Amivantamab combination therapy

Submission of BLA/NDA to FDA and EMA seeking approval of Lazertinib & Amivantamab Combination Therapy

New drug approval of Lazertinib in Korea (Product Name: LECLAZA®)

Receipt of second milestone for Lazertinib

Approval of Phase 3 clinical trial of Lazertinib & Amivantamab
(Johnson & Johnson’s EGFR/C-met Antibody) Combination Therapy

Receipt of first milestone for Lazertinib

Relocation to New HQ in Greater Boston

SKI-G-801 FDA Orphan Drug designation

Approval of Phase 2b clinical trial of Lazertinib

Licensing out of Lazertinib to Janssen ($1.25 billion)

Approval of Phase 2 clinical trial of Cevidoplenib

Private Placement from Oscotec, Yuhan, Jungil 17-1

Approval of Phase 1/2 clinical trial of Lazertinib

Approval of Phase 1 clinical trial of SKI-G-801

Licensing out of GNS-1806 (FGFR4 Inhibitor) to Yuhan

Approval of Phase 1 clinical trial of Cevidoplenib

Licensing out of Lazertinib to Yuhan

Official name change: OCT USA Inc. to Genosco Inc.

Establishment (LA, California)